Ezetimibe is a sterol absorption inhibitor, treatment of hypercholesterolaemia, usually in combination with statins if the treatment with statins alone is not effective enough.
NovEze is indicated for:
co-administered with an HMG-CoA reductase inhibitor (statin) is indicated as adjunctive therapy to a diet for patients with primary (heterozygous familial or non-familial) hypercholesterolaemia who do not respond adequately to the treatment with statins alone.
in monotherapy, it is indicated as adjunctive therapy to a diet for patients with primary (heterozygous familial or non-familial) hypercholesterolaemia for whom statin administration is not considered appropriate or is not tolerated.
Prevention of cardiovascular events:
indicated to reduce the risk of cardiovascular events of patients with ischemic heart disease (IHD) and a history of acute coronary syndrome (ACS) when added to existing statin therapy or when newly co-administered with statins.
Homozygous familial hypercholesterolemia (HoFH):
co-administered with statins is indicated as adjunctive therapy to a diet of patients with HoFH. Patients may also receive adjunctive therapy (eg LDL apheresis).
The obligation to establish a Publicly Accessible Professional Information Service (PAPIS)
result from Act No. 378/2007 Sb., O léčivech. Information on our products can be
found on the website of the State Institute for Drug Control (SÚKL) in the
Product information (SPC or PIL) is available by clicking on the product name and the
Summary of Product Characteristics (SPC) link.
The Publicly Accessible Professional Information Service (PAPIS) for Noveze
is operated by the marketing authorization holder - Pharma-Service International s.r.o., contact: